Combo immunotherapy may herald new standard of care for kidney cancer – Science Daily
The Sun |
Combo immunotherapy may herald new standard of care for kidney cancer
Science Daily Targeted therapies have prolonged life expectancy, but are associated with daily side effects. Single-agent immunotherapies improve patients' survival, but only benefit a subset of patients. Combination immunotherapy with nivolumab and ipilimumab as … Measuring T Cell Levels May Help Identify Patient Response to Immunotherapy What is immunotherapy, could Bradley Lowery be helped by the cancer treatment cost and how much does it cost? Combo immunotherapy may change treatment for kidney cancer |
